03:33 AM EDT, 08/27/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) said Thursday that China's drug regulator officially accepted its marketing authorization application for the oral version of its GLP-1 weight-loss drug Wegovy. The application to China's National Medical Products Administration is based on results of the phase 3 Oasis clinical trial program, which evaluated oral semaglutide tablets for obesity treatment, the Danish drugmaker said. The program, which comprised four trials, assessed 1,300 adult patients with obesity or who were overweight with at least one related comorbidity across multiple countries and regions worldwide, including China.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.